Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track.
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis remains on track for mid-2024 Positive 12-month.
The CAR T-Cell Therapy Market is at the forefront of revolutionary advancements in cancer treatment, heralding a new era in personalized medicine. This innovative approach involves modifying a patient’s own T cells to express Chimeric Antigen Receptors (CARs), enabling them to recognize and attack cancer cells with.
Selecta Biosciences Inc SELB and Cartesian Therapeutics Inc announced a reverse merger in an all-stock deal, with Selecta shareholders owning 26.9% of the new…
Selecta Biosciences (SELB) to Merge with Cartesian Therapeutics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.